How new metabolites affect valvular heart disease
Mechanism and Effect of Novel Metabolites on Valvular Heart Disease（Hestia Study）
This project will test whether newly identified metabolites influence disease progression and outcomes in adults with valvular heart disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 4000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Sun Yat-sen University Academic / other |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT07065500 on ClinicalTrials.gov |
What this trial studies
This is an observational, long-term follow-up study of adults with clinically diagnosed valvular heart disease conducted at the First Affiliated Hospital of Sun Yat-sen University. Investigators will collect clinical data and biological specimens, then perform metabolite testing on tissue samples to identify novel metabolic markers. The study aims to link metabolic signatures to risk factors, mechanisms of valve damage, and patient prognosis. Results will be used to generate hypotheses for future diagnostic biomarkers or targeted interventions.
Who should consider this trial
Good fit: Adults aged 18 or older with a clinical diagnosis of any form of valvular heart disease who can give informed consent are ideal candidates.
Not a fit: People without valvular heart disease, those unable to provide informed consent, or those looking for an immediate therapeutic intervention are unlikely to benefit directly.
Why it matters
Potential benefit: If successful, the study could identify metabolic markers that help predict who will worsen and point to new targets for earlier or more personalized treatment.
How similar studies have performed: Metabolomics has shown promise in other areas of cardiovascular disease, but applying detailed metabolite-mechanism studies specifically to valvular heart disease remains relatively novel and not yet well established.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age ≥18 years, gender is not limited. 2. Clinical diagnosis of heart valve disease (including aortic stenosis, aortic valve closure insufficiency due to different etiologies, mitral stenosis, mitral valve closure insufficiency, pulmonic stenosis, pulmonic valve closure insufficiency, tricuspid stenosis and tricuspid closure insufficiency due to different etiologies ) Exclusion Criteria: Patients unable to provide informed consent
Where this trial is running
Guangzhou, Guangdong
- The First Affiliated Hospital of Sun Yat-sen Univerity — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Study coordinator: Xiaodong Zhuang
- Email: zhuangxd3@mail.sysu.edu.cn
- Phone: +8613760755035
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.